Effects of COVID-19 in Patients with Gastroparesis: A GpCRC Supplement

COVID-19 对胃轻瘫患者的影响：GpCRC 补充剂

• 批准号: 10179037
• 负责人: HENRY PAUL PARKMAN
• 金额: $ 35.21万
• 依托单位: TEMPLE UNIV OF THE COMMONWEALTH
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-15 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10179037
• 关键词: 2019-nCoV; Affect; Antibodies; COVID-19; COVID-19 pandemic; Chronic; Clinic; Clinical; Clinical Data; Clinical Research; Communities; Coughing; Data; Development; Diagnosis; Diarrhea; Disease; Dyspepsia; Enrollment; Etiology; Fever; Flare; Functional Gastrointestinal Disorders; Functional disorder; Funding; Gastric Emptying; Gastrointestinal Diseases; Gastrointestinal tract structure; Gastroparesis; Geographic Locations; Goals; Grant; Immunoglobulin G; Impairment; Infection; Inflammation; Interview; Irritable Bowel Syndrome; Lung; Multicenter Studies; Natural History; Nausea and Vomiting; Outpatients; Pathologic; Patient Recruitments; Patient-Focused Outcomes; Patients; Phenotype; Physiological; Plasma; Population; Population Density; Prevalence; Prospective cohort study; Questionnaires; Recording of previous events; Registries; Research; Research Project Grants; Research Subjects; Respiratory Signs and Symptoms; Risk; Rome; Serologic tests; Seroprevalences; Severities; Shortness of Breath; Stomach; Structure; Suggestion; Symptoms; Testing; TimeLine; United States National Institutes of Health; Universities; Viral Respiratory Tract Infection; Virus; base; clinical center; clinical research site; flu; gastrointestinal; gastrointestinal epithelium; gastrointestinal infection; gastrointestinal symptom; motility disorder; parent grant; patient registry; persistent symptom; receptor; symptom treatment

ABSTRACT: Coronavirus Disease 2019 (COVID-19), a disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), commonly presents with symptoms including fever, cough, and shortness of breath. Some patients have tested positive for SARS-CoV-2 after developing gastrointestinal (GI) symptoms either solely or in conjunction with pulmonary symptoms. This may be due to SARS-CoV-2 infection of the GI tract or a systemic effect from the respiratory viral infection. In patients with chronic GI illnesses, such as gastroparesis, COVID-19 may present as a flare of their underlying GI condition as viruses have historically been implicated in exacerbations of chronic GI disorders, including gastroparesis. Some patients with no underlying GI conditions have been diagnosed with COVID-19 after presenting predominantly with nausea, vomiting and diarrhea. They may be at risk for developing post-viral gastroparesis, which is an important and poorly understood potential chronic inflammation-based cause of “idiopathic gastroparesis”. The NIH Gastroparesis Clinical Research Consortium (GpCRC), consisting of six clinical centers and its Scientific and Data Research Center (SDRC), is following the largest number of patients with gastroparesis and dyspepsia symptoms. These patients are well phenotyped. In addition to detailed physiological phenotyping, every 6 months we obtain detailed questionnaires, and store plasma and serum. The overall goals of this supplemental grant are to determine if COVID-19 affects clinical course of patients with gastroparesis and whether COVID-19 is associated with development of post-infection gastroparesis and/or functional dyspepsia. We will accomplish these goals by undertaking the following three specific aims involving patients in our gastroparesis registry. Aim 1. Determine the prevalence of SARS-CoV-2 infection in patients with confirmed gastroparesis to help assess if SARS-CoV-2 infection disproportionately affects patients with gastroparesis compared to general community population in same geographic location. Aim 2: Determine if COVID-19 affects the clinical course of patients with gastroparesis by causing more flares than usual, increasing the severity of gastroparesis symptoms, and decreasing gastric emptying. Aim 3: Characterize patients developing new onset gastroparesis and functional dyspepsia after COVID-19 in patients. Currently, the GpCRC is the only large, NIH-funded registry of patients with chronic GI symptoms from gastric dysmotility (gastroparesis). The GI epithelial involvement with SARS-CoV-2 as well as the existing rationale that such infections can led to chronic gut dysfunction, makes GpCRC ideally poised to conduct this research. This research project will be accomplished within 1 year timeline to produce impactful clinical data to understand GI implications of SARS-CoV-2 infection. This proposed study will be implemented at all six clinical sites of the GpCRC with SDRC for coordination and Mayo Clinic core of the GpCRC will be used for SARS-CoV-2 serology testing.

抽象的： 2019 年冠状病毒病 (COVID-19)，一种由严重急性呼吸道感染引起的疾病 冠状病毒 2 综合征 (SARS-CoV-2)，通常出现发烧、咳嗽等症状 一些患者出现胃肠道症状后检测出 SARS-CoV-2 呈阳性。 单独出现胃肠道症状或与肺部症状同时出现 这可能是由 SARS-CoV-2 引起的。 胃肠道感染或呼吸道病毒感染的全身影响。 胃轻瘫等疾病，COVID-19 可能会表现为潜在胃肠道疾病的突然发作： 历史上，病毒与慢性胃肠道疾病（包括胃轻瘫）的恶化有关。 一些没有潜在胃肠道疾病的患者在就诊后被诊断出患有 COVID-19 主要表现为恶心、呕吐和腹泻，他们可能有感染后病毒的风险。 胃轻瘫，这是一种重要且知之甚少的潜在慢性炎症原因 “特发性胃轻瘫”。NIH 胃轻瘫临床研究联盟 (GpCRC)，由六个成员组成。 临床中心及其科学和数据研究中心 (SDRC)，正在追随数量最多的 胃轻瘫和消化不良症状的患者也有很好的表现。 详细的生理表型分析，每6个月我们获得详细的调查问卷，并储存血浆 这笔补充拨款的总体目标是确定 COVID-19 是否影响临床。 胃轻瘫患者的病程以及 COVID-19 是否与胃轻瘫的发展相关 感染后胃轻瘫和/或功能性消化不良我们将通过以下方式实现这些目标。 目标1。 确定确诊胃轻瘫患者中 SARS-CoV-2 感染的患病率，以帮助评估 与一般胃轻瘫患者相比，SARS-CoV-2 感染是否对胃轻瘫患者造成不成比例的影响？ 目标 2：确定 COVID-19 是否影响临床。 胃轻瘫患者的病程会比平常引起更多的发作，从而增加胃轻瘫的严重程度 目标 3：描述出现新症状的患者的特征。 目前，GpCRC 是唯一治疗 COVID-19 后出现胃轻瘫和功能性消化不良的药物。 由美国国立卫生研究院 (NIH) 资助的大型登记册，登记因胃动力障碍（胃轻瘫）而出现慢性胃肠道症状的患者。 SARS-CoV-2 涉及胃肠道上皮以及此类感染可能导致的现有原理 慢性肠道功能障碍使得 GpCRC 非常适合开展这项研究项目。 在 1 年内完成，产生有影响力的临床数据，以了解 GI 的影响 这项拟议的研究将在 GpCRC 的所有六个临床中心实施。 SDRC 负责协调，梅奥诊所 GpCRC 核心将用于 SARS-CoV-2 血清学检测。